Skip to Main Content

Jill Lacy, MD

Professor of Medicine (Medical Oncology)

Contact Information

Jill Lacy, MD

Mailing Address

  • Medical Oncology

    PO Box 208028

    New Haven, CT, 06520-8028

    United States

Research Summary

Dr. Jill Lacy is a Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine. She has a large clinical practice in the Gastrointestinal Malignancies Unit at Smilow Cancer Center, and she has been actively engaged in clinical investigation, focusing on therapeutic clinical trials. She has developed and conducted several investigator-initiated trials in gastrointestinal malignancies, and, in addition, has served as the site Principle Investigator on dozens of cooperative group and industry sponsored trials, leading to co-authorship in high impact journals. Her specific research interests include discovery of novel therapeutics for gastroesophageal and pancreatic cancers. In her role as an investigator in the Smilow Cancer Center Disease Aligned Research Team for GI Malignancies, she has been instrumental in developing the clinical trials portfolio and fostering translational research for GI Cancers at Yale.

Extensive Research Description

Dr. Jill Lacy is a Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine. She has a large clinical practice in the Gastrointestinal Malignancies Unit at Smilow Cancer Center. After transitioning from lab-based basic research in the field of EBV-associated malignancies, she has been actively engaged in clinical investigation, focusing on therapeutic clinical trials. She has developed and conducted several investigator-initiated trials, and, in addition, has served as the site Principle Investigator on dozens of cooperative group and industry sponsored trials, leading to co-authorship in high impact journals. Her specific research interests include discovery of novel therapeutics for gastroesophageal and pancreatic cancers. In her role as an investigator in the Smilow Cancer Center Disease Aligned Research Team for GI Malignancies, she has been instrumental in developing the clinical trials portfolio and fostering translational research for GI Cancers at Yale. In addition to her involvement in patient care and research, Dr. Lacy served at the Program Director of the Hematology-Medical Oncology Fellowship Program at Yale for over 20 years, playing an active role in mentoring Fellows in their research projects and development. Aligned with this commitment to education, she has been actively involved in ASCO in issues related to trainee education, including service as Editor of the ASCO Self-Evaluation Program.

Public Health Interests

Cancer; Clinical Trials

Clinical Trials

ConditionsStudy Title
LiverA Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Colon; RectumPhase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Colon; RectumRandomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Liver; Lung; Melanoma, skin; Other Female GenitalPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
LiverA Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
PancreasA Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Colon; RectumA Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
ColonRandomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
AnusA Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Lung; PancreasA Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP
Colon; RectumA Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Colon; RectumA Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)
Anus; Colon; Esophagus; Kidney; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Stomach; Thyroid; Unknown Sites; Breast; Urinary BladderDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
StomachA Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Anus; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kaposi's sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Cervix; Urinary BladderNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
ColonS0820, Adenoma and Second Primary Prevention Trial (PACES)